Are you searching for the best growth stocks for 2026? The Mid Cap Improvers portfolio is designed as a powerful sector ETF alternative, focusing on undervalued mid-cap companies in the healthcare sector with strong potential for capital appreciation. With a Tradestie Score of 67.24/100, this portfolio targets high-growth opportunities by zeroing in on innovative firms poised to outperform in the evolving healthcare landscape. Whether you're exploring value investing or seeking exposure to healthcare stocks, this strategy offers a unique entry point for Q1 2026 gains.
At the heart of this portfolio are two standout holdings: Alkermes Plc (ALKS) and Aclaris Therapeutics Inc (ACRS). Alkermes (ALKS), comprising 66.6% of the portfolio, is a leader in biopharmaceuticals with a robust pipeline of treatments for central nervous system disorders, making it one of the top healthcare stocks to watch for 2026. Aclaris Therapeutics (ACRS), holding 33.4%, is gaining traction with its cutting-edge dermatology and immunology solutions, positioning it as an undervalued stock with significant upside potential based on current valuations. Both companies are selected for their innovation, market positioning, and growth catalysts in the healthcare sector, aligning with the 2026 market outlook for increased healthcare spending.
Tailored for aggressive growth investors and those building a retirement portfolio, Mid Cap Improvers appeals to individuals comfortable with concentrated sector bets. However, with a diversification score of just 2.3/100 and 100% allocation to healthcare, investors must consider market risks like regulatory changes, clinical trial setbacks, and sector-specific volatility. If you're a beginner investor or seeking passive income, this may not be the ideal fit. For those eyeing the best growth stocks in healthcare for 2026, this portfolio offers a compelling, albeit focused, opportunity.